

RESEARCH PROJECTS

Burke W: Whole abdominal radiotherapy versus combination doxorubicin-cisplatin chemotherapy in advanced endometrial carcinoma. GOG.

Burke W: A phase III randomized study of cisplatin (NSC #119875) and paclitaxel (NC #125973) with interval secondary cytoreduction versus cisplatin and paclitaxel in patients with suboptimal stage III epithelial ovarian carcinoma. GOG.

Burke W: A phase II trial of STI571 for the treatment of platinum and taxane refractory stage III and IV epithelial ovarian cancer and primary peritoneal cancer. SWOG.

Burke W: A phase III randomized trial of paclitaxel and carboplatin versus triplet or sequential doublet combinations in patients with epithelial ovarian or primary peritoneal carcinoma. GOG.

Burke W: A phase III randomized study of pegylated liposomal doxorubicin plus carboplatin versus carboplatin in platinum-sensitive patients with recurrent epithelial ovarian or peritoneal carcinoma after failure of initial, platinum-based chemotherapy. SWOG.

Burke W: A phase II evaluation of cetuximab and carboplatin in the treatment of recurrent platinum-sensitive epithelial ovarian or primary peritoneal cancer. GOG.

Burke W: Phase III randomized study of TLK286 versus doxil/caelyx or hycamtin as third-line therapy in platinum refractory or resistant ovarian cancer.

Johnston C: A randomized study of tamoxifen versus thalidomide (NSC#66847) in patients with biochemical-recurrence-only epithelial ovarian cancer, cancer of the fallopian tube, and primary peritoneal carcinoma after first line chemotherapy. GOG.

Krauss J: A prospectively randomized, phase III, multi-center, controlled trial to evaluate the safety and efficacy of the zevalin therapeutic regimen plus rituxan compared with rituxan alone in patients with relapsed or refractory follicular non-hodgkin's lymphoma. IDEC.

Krauss J: A controlled, randomized, phase III, multi-center, open label study of ABI-007 (a cremophor-free, protein stabilized, nanoparticle paclitaxel) and taxol in patients with metastatic breast cancer. AMERR BIO.

Krauss J: A phase II study of VELCADE in subjects with relapsed or refractory mantle cell lymphoma. Millennium.

Krauss J: An open label phase II study of E7070 in metastatic breast cancer patients previously treated with an anthracycline, a taxane and capecitabine (or fluoropyrimidine).

Krauss J: The National Lymphocare Study: An observational study of treatment, outcomes, and prognosis in patients with follicular non-hodkin's lymphoma.

Northouse L: Outcomes of triaged family care in advanced cancer. GRP C.

Stella P: Evaluation of adjuvant therapy in node negative operable female breast cancer. EST.

Stella P: Phase III placebo-controlled, randomized, double-blind comparison of etanercept (enbrel) versus placebo for the treatment of cancer-associated weight loss and anorexia. NCCTG.

RESEARCH PROJECTS (CONT.)

Stella P: The use of ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction. NCCTG.

Stella P: The use of valeriana officinalis (valerian) in improving sleep in patients who are undergoing adjuvant treatment for cancer: A phase III randomized, placebo-controlled, double-blind study. NCCTG.

Stella P: Randomized phase II study of interleukin-12 in combination with rituximab in patients with non-hodgkin's lymphoma. NCCTG.

Stella P: Randomized phase III study of docetaxel or pemetrexed with or without cetuximab in patients with recurrent or progressive non-small cell lung cancer after platinum-based therapy.

Stella P: Adjuvant androgen deprivation versus mitoxantrone plus prednisone plus androgen deprivation in selected high risk prostate cancer patients following radical prostatectomy, phase III. SWOG.

Stella P: Effect of acupuncture on nausea in women treated for breast cancer. MDA.

Stella P: Phase II study of accelerated high dose thoracic irradiation with concurrent chemotherapy for patients with limited small cell lung cancer. RTOG.

Stella P: Phase III prospective randomized study of adjuvant chemotherapy with vinorelbine and cisplatin in completely resected non-small cell lung cancer with companion tumor marker evaluation. ECOG.

Stella P: A phase III randomized study of TLK286 (Telcyta) versus gefitinib (Iressa®) as third-line therapy in locally advanced or metastatic non-small cell lung cancer.

Stella P: A phase II study of a combination of MTA (LY231514) and gemcitabine in patients with metastatic breast cancer.

Stella P: A randomized phase III trial of gemcitabine plus bevacizumab (NSC#704865) versus gemcitabine plus placebo in patients with advanced pancreatic cancer. CTSU/NCCTG.

Stella P: A randomized, placebo-controlled, double-blind trial evaluating the effects of exemestane in clinical Stage T1-3N0-1M0 postmenopausal breast cancer patients of tamoxifen therapy.

Stella P: A randomized, placebo-controlled, double-blind, trial of the administration of the MDR modulator, zosuquidar trihydrochloride, during conventional induction and post-remission therapy in patients greater than 60 years of age with newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation of high-risk refractory anemia with excess blasts in transformation of high-risk refractory anemia with excess blasts.

Stella P: Phase III randomized trial of chemotherapy alone versus chemotherapy plus radiotherapy consolidation for unfavorable (diffuse) histologic subtypes of early stage non-hodgkin's lymphoma. EST.

Stella P: Post-operative adjuvant alpha-2 recombinant interferon in high-risk melanoma. EST.

Stella P: A phase III comparison of CHOP versus m-BACOD versus ProMace-Cyta-BOM versus MACOP-B in patients with intermediate or high grade non-hodgkin's lymphoma. EST.

Stella P: Phase II study of rituximab (NSC 687451) + CHOP followed by 90Y-irbritumomab tiuxetan. EST.

RESEARCH PROJECTS (CONT.)

Stella P: Phase III comparison of combination chemotherapy (CAF) and chemohormonal therapy (CAF + zoladex + tamoxifen) in premenopausal women with axillary node-positive receptor-positive breast cancer (intergroup). EST.

Stella P: Phase III comparison of adjuvant chemotherapy with or without endocrine therapy in high-risk, node negative breast cancer patients, and a natural history follow-up study in low-risk, node negative patients. EST.

Stella P: A randomized phase III trial comparing ABVD versus MOPP/ABV hybrid for advanced Hodgkin's disease. EST.

Stella P: A clinical trial comparing oral uracil/ftorafur (UFT) plus leucovorin (LV) with 5-fluorouracil (5-fu) plus LV in the treatment of patients with stages II and III carcinoma of the colon. NSABP.

Stella P: Phase III study of radiation therapy, levamisole and 5-fluorouracil versus 5-fluorouracil and levamisole in selected patients with completely resected colon cancer. NCCTG.

Stella P: Phase III double-blind randomized trial of 13-Cis Retinoic (13-cRA) to prevent second primary tumors (SPTs) in stage I non-small cell lung cancer. NCCTG.

Stella P: A phase III evaluation of high-dose levamisole plus 5-fluorouracil and leucovorin as surgical adjuvant therapy for high-risk colon cancer. NCCTG.

Stella P: Phase III comparison of adjuvant chemotherapy with high-dose cyclophosphamide plus doxorubicin (AC) versus sequential doxorubicin followed by cyclophosphamide (A-C) in high-risk breast cancer patients with 0-3 positive nodes. NCCTG.

Stella P: A sequential approach to the treatment of muscle invasive, non-metastatic carcinoma of the bladder: A phase II trial of neoadjuvant gemcitabine, paclitaxel and carboplatin with molecular correlates. SWOG.

Stella P: A randomized trial evaluating the worth of paclitaxel (taxol) following doxorubicin (adriamycin)/cyclophosphamide in breast cancer patients with positive axillary nodes. NSABP.

Stella P: A phase II study of sequential combination chemotherapy with cyclophosphamide and 2-CDA in previously untreated patients with B-CLL. NCCTG.

Stella P: A randomized phase III study in low grade lymphoma comparing cyclophosphamide/fludarabine to standard therapy followed by maintenance anti-CD20 antibody. EST.

Stella P: A phase III trial of carboplatin, paclitaxel and thoracic radiotherapy, with or without thalidomide, in patients with stage III NSCLC (ECOG E 3598).

Stella P: A randomized phase III study comparing ABVD vs. MOPP/ABV hybrid in treatment of advanced Hodgkin's disease. SWOG.

Stella P: A phase III double-blind randomized trial of 12-Cis retinoic acid (12-cRA) to prevent secondary primary tumors (SPTS) in stage I non-small cell lung cancer. SWOG.

Stella P: Enhancing well-being during breast cancer recurrence. SWOG.

Stella P: Randomized trial of post-mastectomy radiotherapy in stages II breast cancer in women with one to three positive axillary nodes, phase III. SWOG.

RESEARCH PROJECTS (CONT.)

Stella P: A randomized phase III trial of surgery alone or surgery plus pre-operative paclitaxel/carboplatin in clinical stage IB (T2N0), II (T1-T2N1, T3N0), and selected IIIA (T3N1) non small cell lung cancer. NCCTG.

Stella P: A clinical trial to determine the worth of tamoxifen and the worth of breast radiation in the management of patients with node-negative, occult, invasive breast cancer treated by lumpectomy. NSABP.

Stella P: A clinical trial to evaluate the worth of pre-operative multimodality therapy (5FU/LV and RTX) in patients with operable carcinoma of the rectum. NSABP.

Stella P: A phase III trial of etoposide plus cisplatin chemotherapy plus standard versus accelerated hyperfractionated thoracic radiation in stage IIIA/B non-small cell lung cancer. NCCTG.

Stella P: A randomized trial comparing pre-operative doxorubicin (adriamycin), cyclophosphamide (AC) to pre-operative AC followed by pre-operative docetaxel (taxotere) and to pre-operative AC followed by post-operative docetaxel in patients with operable cancer of the breast. NSABP.

Stella P: Intermittent androgen suppression in patients with D2 prostate cancer, phase III. SWOG.

Stella P: A phase III randomized, placebo-controlled, double-blind trial of risedronate (Actonel) for prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast carcinoma. NCCTG.

Stella P: A phase III study of evaluation of lumpectomy, tamoxifen, and irradiation of the breast compared with lumpectomy plus tamoxifen in women 70 years of age or older who have carcinoma of the breast that is less than or equal to 2cm and clinically negative axillary nodes. EST.

Stella P: A phase II trial of 2-CDA in previously treated or untreated patients with mantle cell lymphoma. NCCTG.

Stella P: A phase III study of adjuvant chemotherapy after resection for patients with TxNO stage I non-small cell lung cancer. NCCTG.

Stella P: A phase III randomized double-blind study of letrozole versus placebo in women with primary breast cancer completing five or more years of adjuvant Tamoxifen JMA. NCCTG.

Stella P: A randomized, phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients. NSABP.

Stella P; A randomized phase III trial of ABVD versus Stanford v + radiation therapy in locally extensive and advanced stage hodgkin's disease with 0-2 risk factors. EST.

Stella P: Phase III comparison of adjuvant chemoendocrine therapy with CAF and concurrent or delayed Tamoxifen to Tamoxifen alone in postmenopausal patients with involved axillary lymph nodes and positive receptors. SWOG.

Stella P: A phase III comparison of cyclophosphamide doxorubicin and 5-fluorouracil (CAF) and a 16-week multi-drug regimen as adjuvant therapy for patients with hormone receptor negative breast cancer. SWOG.

Stella P: A phase III randomized trial comparing intermittent versus continuous androgen suppression for patients prostate-specific-antigen progression in the clinical absence of distant metastases following radiotherapy for prostate cancer. SWOG.

RESEARCH PROJECTS (CONT.)

Stella P: A phase III randomized trial of autologous and allogeneic bone marrow transplantation versus intensive conventional chemotherapy in acute lymphoblastic leukemia in first remission. EST.

Stella P: A randomized phase III equivalence trial of irinotecan (cpt-11) versus oxaliplatin (oxal)/5-fluorouracil (5-fu)/leucovorin (cf) in patients with advanced colorectal carcinoma previously treated with 5-fu. NCCTG.

Stella P: A multi-center evaluation of breast cancer patterns and outcomes of care within the National Comprehensive Cancer Network (NCCN) conducted at community level. A collaborative effort between the University of Michigan Cancer Center Network (UMCCN) and Saint Joseph Mercy Health System. NCCN.

Stella P: A phase II multi-center study of erbitux (cetuximab) in patients with metastatic colorectal carcinoma. IMCLONE.

Stella P: A randomized, open label study to assess time to hemoglobin response of a front load dosing regimen for darbepoetin alfa compared to a weekly dose regimen for recombinant human erythropoietin in patients with non-myeloid malignancies receiving chemotherapy. AMGEN.

Stella P: A phase III, randomized study of two different dosing schedules of erythropoietin in anemic patients with cancer. NCCTG.

Stella P: Pharmacokinetic companion to protocol IMCL CP02-0144: A phase II multi-center study of erbitux (cetuximab) in patients with metastatic colorectal carcinoma. IMCLONE.

Stella P: Anti-epidermal growth factor (EGFR) antibody, cetuximab (C225), in patients with stage IV colorectal carcinoma who failed all standard therapy: An access protocol. BRISTOL.

Stella P: A phase III prospective randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor antagonist ZD1839 (IRESSA) in completely resected primary stage IB, II and IIIA non-small cell lung cancer. NCCTG.

Stella P: A phase IIIb randomized, double-blind study comparing maintenance ZD1839 (IRESSA) or placebo following completion of front line, platinum-based, double chemotherapy in subjects with advanced or metastatic non-small cell lung cancer.

Stella P: A two part, multiple dose clinical trial of the safety and efficacy of ABX-EGF in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. UNK.

Stella P: A Phase III randomized, open-label, multi-center study of irinotecan and cetuximab versus irinotecan as second-line treatment in patients with metastatic, EGFR-positive colorectal carcinoma. BRISTOL.

Stella P: An open-label randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (Q3W) ("XELOX") versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin (Q2W) ("FOLFOX4") as first-line treatment for patients with metastatic colorectal cancer. NA.

Stella P: A phase III clinical trial comparing pre-operative radiation therapy and capecitabine with preoperative radiation therapy and continuous intravenous infusion (CVI) of 5-fluorouracil (5-FU) in the treatment of patients with operable carcinoma of the rectum. NSABP.

Stella P: A randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer. NSCLC.

RESEARCH PROJECTS (CONT.)

Stella P: A clinical trial of the safety and efficacy of ABX-EGF as a second-line treatment for advanced non-small cell lung cancer. IMMUNEX.

Stella P: An 2'2 factorial randomized phase III study of intermittent oral capecitabine in combination with intravenous oxaliplatin (Q3W) ("XELOX") with/without intravenous bevacizumab (Q3W) versus bolus and continuous infusion fluorouracil/intravenous leucovorin with intravenous oxaliplatin.

Stella P: A clinical trial to evaluate the worth of tamoxifen in conjunction with lumpectomy and breast irradiation for the treatment of noninvasive intraductal carcinoma (DCIS) of the breast (B-24). NSABP.

Stella P: A clinical trial to determine the worth of tamoxifen for preventing breast cancer. NSABP.

Stella P: Breast cancer prevention trial (BCPT) amendment: Extension of follow-up to assess the long term outcome of the participants of the BCPT. NSABP.

Stella P: Chemoprevention of prostate cancer with finasteride (proscar) phase III. SWOG.

Stella P: Chemoprevention of prostate cancer with finasteride (proscar), phase III collection and storage of white blood cells and plasma for additional biological studies. SWOG.

Stella P: Chemoprevention of prostate cancer with finasteride (proscar) phase III. extended follow-up. SWOG.

Stella P: Phase III chemoprevention trial of selenium supplementation in persons with resected stage I non-small cell lung cancer. ECOG.

Stella P: Phase III randomized study of adjuvant immunotherapy with monoclonal antibody 17-1A versus no adjuvant therapy following resection for stage II (modified aster-collar B2) adenocarcinoma of the colon. NCCTG.

Stella P: Prostate cancer: Impact of fat - & flaxseed – modified diets. UMCC.

Stella P: Retinoids and intermediate biomarkers for CIN II and III. UMCC.

Stella P: A phase III comparison of adjuvant chemotherapy with high dose cyclophosphamide plus doxorubicin (AC) versus sequential doxorubicin followed by cyclophosphamide (AC) in high risk breast cancer patients with 0 - 3 positive nodes. SWOG.

Stella P: A phase II study of taxotere and CPT-11 in patients with advanced adenocarcinoma of the lower esophagus, esophagogastric junction and gastric cardia. NCCTG.

Stella P: A randomized phase II study in operable adenocarcinoma of the esophagus to measure response rate and toxicity of pre-operative combined modality paclitaxel /cisplatin/RT or irinotecan/cisplatin/RT followed by post-operative chemotherapy with the same agents. ECOG.

Stella P: A phase III trial of high dose interferon alpha-2b versus cisplatin, vinblastine, DTIC plus IL-2 and interferon in patients with high risk melanoma. SWOG.

Stella P: Selenium and vitamin E cancer prevention trial. SWOG.

Stella P: A study comparing clodronate therapy with placebo in patients with early-stage breast cancer. NSABP.

RESEARCH PROJECTS (CONT.)

Stella P: Phase III randomized, intergroup, international trial assessing the clinical activity of STI-571 at two dose levels in patients with unresectable or metastatic malignant gastrointestinal stromal tumors (GIST) expressing the KIT receptor tyrosine kinase. SWOG.

Stella P: A phase II study of topical ceramide lipids as treatment for cutaneous breast cancer. NCCTG.

Stella P: A phase II study of thalidomide in the treatment of myelodysplastic syndrome in adults: A clinical and biologic study. NCCTG.

Stella P: Phase III randomized study of concurrent tretinoin and chemotherapy with or without arsenic trioxide (As₂O₃) (NSC #706363) as initial consolidation therapy followed by maintenance therapy with intermittent tretinoin versus intermittent tretinoin plus mercaptopurine and methotrexate for patients with untreated acute promyelocytic leukemia. EST.

Stella P: A phase III trial of cisplatin/etoposide/radiotherapy with consolidation docetaxel followed by maintenance therapy with ZD1839 or placebo in patients with inoperable locally advanced stage III non-small cell lung cancer. NCCTG.

Stella P: Effects of selective estrogen receptor modulators on cognitive aging: Cognition in the study of tamoxifen and raloxifene. UNK.

Stella P: Colon cancer screen: Fecal blood versus EXACT. NCCTG.

Stella P: Phase II trial of faslodex in women with metastatic breast cancer and failure on aromatase. NCCTG.

Stella P: A phase III trial of CHOP versus CHOP + rituximab versus CHOP + iodine-131-labeled monoclonal anti-B1 antibody (tositumomab) for treatment of newly diagnosed follicular non-hodgkin's lymphomas. SWOG.

Stella P: Randomized phase II/III trial of paclitaxel plus carboplatin with or without bevacizumab (NSC #704865) in patients with advanced nonsquamous. ECOG.

Stella P: A randomized phase III trial of interferon alfa-2B or interferon alfa-2B plus bevacizumab in patients with advanced renal carcinoma. CTSU/CALGB.

Stella P: Phase II study of weekly irinotecan and docetaxel in patients with refractory metastatic breast cancer.

Stella P: A phase II, randomized, open-label study of single agent CI-1033 in patients with advanced non-small cell lung cancer.

Stella P: A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin LV and oxaliplatin with 5-FU LV for the treatment of patients with stages II and III carcinoma of the colon. NSABP.

Stella P: A phase II clinical trial evaluating three schedules of ALIMTA plus GEMZAR as front-line chemotherapy for patients with locally advanced or metastatic non-small cell lung cancer. NCCTG.

Stella P: Phase III trial of bevacizumab (NSC 704865), oxaliplatin (NSC 266046), fluorouracil and leucovorin versus oxaliplatin, fluorouracil and leucovorin versus bevacizumab alone in previously treated patients with advanced colorectal cancer. ECOG.

Stella P: A phase III randomized multi-center study of cetuximab, oxaliplatin, 5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and leucovorin in patients with previously treated metastatic, EGFR-positive colorectal carcinoma.

RESEARCH PROJECTS (CONT.)

Stella P: Phase II study of gemcitabine and epirubicin for the treatment of mesothelioma. NCCTG.

Stella P: A phase III clinical trial of adjuvant therapy comparing six cycles of 5-fluorouracil, epirubicin and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) with or without celecoxib, in patients with node-negative breast cancer. NSABP.

Stella P: A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab (rhuMAb VEGF) as first line therapy for locally recurrent or metastatic breast cancer. ECOG.

Stella P: Phase II trial of chronic oral ZD1839 (iressa) in both previously untreated and previously treated patients with selected stage IIIB and IV bronchioloalveolar carcinoma. SWOG.

Stella P: Lung cancer specimen repository protocol, ancillary. SWOG.

Stella P: Phase III comparison of depo medroxyprogesterone acetate (DPROV) to venlafaxine for managing hot flashes. NCCTG.

Stella P: A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men. NCCTG.

Stella P: The efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: A phase III randomized, double-blind, placebo-controlled, crossover trial (NCCTG N00C3). NCCTG.

Stella P: A phase II study of CCI-779 in previously treated patients with mantle cell non-hodgkin's lymphoma. NCCTG.

Stella P: A phase II evaluation of gleevec (imatinib mesylate (IND#61135, NSC #716051) in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma. GOG.

Stella P: Phase II study of topotecan and paclitaxel followed by high-dose thoracic radiation therapy with concomitant cisplatin/etoposide and amifostine in limited-stage small cell lung cancer. NCCTG.

Stella P: Cyclophosphamide and doxorubicin (CA) (4 versus 6 cycles) versus paclitaxel (12 weeks versus 18 weeks) as adjuvant therapy for women with node-negative breast cancer: A 2x2 factorial phase III randomized study. NCCTG.

Stella P: A phase II study of oxaliplatin and capecitabine in patients with measurable metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia. NCCTG.

Stella P: Phase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. UMCC.

Stella P: A prospective observational biologic study of asymptomatic patients with monoclonal gammopathy and plasma proliferative disorders. SWOG.

Stella P: Randomized phase III trial of cisplatin and irinotecan (NSC-616348) versus cisplatin and etoposide in patients with extensive stage small cell lung cancer. NCCTG.

Stella P: A randomized phase II trial of PS-341 and gemcitabine in patients with metastatic pancreatic adenocarcinoma. NCCTG.

Stella P: Phase II evaluation of carboplatin, paclitaxel and gemcitabine followed by concurrent cisplatin and radiation therapy in patients with locally advanced or recurrent urothelial malignancy. SWOG.

RESEARCH PROJECTS (CONT.)

Stella P: A phase II study of gemcitabine, cisplatin and radiation therapy in patients with locally advanced pancreatic cancer. NCCTG.

Stella P: Phase III intergroup trial of adjuvant chemoradiation after resection of gastric or gastroesophageal adenocarcinoma. NCCTG.

Stella P: A clinical trial comparing anastrozole with tamoxifen in postmenopausal patients with ductal carcinoma in situ (DCIS) undergoing lumpectomy with radiation therapy. NSABP.

Stella P: Randomized study of gemcitabine (fixed-dose infusion) and oxaliplatin (NSC 266046) versus gemcitabine (fixed-dose rate infusion) versus gemcitabine (30-minute infusion) in pancreatic carcinoma. ECOG.

Stella P: A phase II trial evaluating atrasentan in patients with advanced renal cell carcinoma. ECOG.

Stella P: Phase II trial of STI571 in patients with relapsed small-cell lung cancer. NCCTG.

Stella P: Randomized double-blind study of adjuvant STI571 (Gleevec) versus placebo in patients following the resection of primary gastrointestinal stromal tumor. NCCTG.

Stella P: Long-term follow-up protocol: An administrative tool. SWOG.

Stella P: Intergroup randomized phase III study of postoperative irinotecan, 5-fluorouracil and leucovorin versus oxaliplatin, 5-fluorouracil and leucovorin versus 5-fluorouracil and leucovorin for patients with stage II or III rectal cancer receiving either preoperative radiation and 5-fluorouracil or postoperative radiation and 5-fluorouracil. ECOG.

Stella P: A phase II trial of induction chemoradiotherapy with cisplatin/etoposide followed by surgical resection followed by docetaxel, for non-small cell lung cancer involving the superior sulcus (pancoast tumors). SWOG.

Stella P: A randomized phase II trial of combination anastrozole (NSC #719344) plus ZD1839 (Iressa, NSC #715055, IND #61187) and of combination fufestrant (NSC #719276) plus ZD1839 in the treatment of postmenopausal women with hormone receptor-positive metastatic cancer. ECOG.

Stella P: Phase II trial of CPT-11 and radiation followed by CPT-11 and BCNU in glioblastoma multiforme patients. NCCTG.

Stella P: Phase II trial of doxorubicin and gemcitabine in metastatic renal cell carcinoma with sarcomatoid features. ECOG.

Stella P: A randomized phase III trial of irinotecan (CPT-11) and/or oxaliplatin (OXAL) plus 5-fluorouracil (5-FU)/leucovorin (CF) after curative resection for patients with stage III colon cancer. GRP C.

Stella P: Randomized phase III trial comparing two different rituximab dosing regimens for patients with low tumor burden indolent non-hodgkin's lymphoma. GRP C.

Stella P: Randomized phase II study of interleukin-12 combination with rituximab in patients with non-hodgkin's lymphoma. NCCTG.

Stella P: Phase II of rituximab and 2-chlorodeoxyadenosine(2-CDA) in newly diagnosed mantle cell lymphoma. GRP C.

Stella P: The efficacy of lamotrigine in the management of chemotherapy-induced peripheral neuropathy: A phase II randomized, double-blind, placebo-controlled trial (NCCTG N01C3). NCCTG.

RESEARCH PROJECTS (CONT.)

Stella P: A phase II trial of PS-341 (NSC-681239) in patients with platinum-treated extensive stage small-cell cancer. SWOG.

Stella P: Phase III Trial of Continuous Schedule AC+G Vs Q2 Week Schedule AC, Followed by Paclitaxel Given Either Every 2 Weeks or Weekly for 12 Weeks as Post-Operative Adjuvant Therapy in Node-Positive or High-Risk Node Negative Breast Cancer (SWOG S0221). SWOG.

Stella P: A phase II study of ZD1839 (Iressa, Gefitinib, NSC 715055) in advanced unresectable hepatocellular carcinoma. ECOG.

Stella P: A phase III trial evaluating the role of exemestane plus GnRH analogue as adjuvant therapy for premenopausal women with endocrine responsive breast cancer. CTSU.

Stella P: A phase III trial evaluating the role of ovarian function suppression and the role of exemestane as adjuvant therapies for premenopausal women with endocrine responsive breast cancer. CTSU.

Stella P: The use of low dose testosterone to enhance libido in female cancer survivors: A phase III randomized, placebo-controlled, double-blind crossover study. NCCTG.

Stella P: Postoperative evaluation of 5FU by bolus injection versus 5FU by prolonged venous infusion prior to and following combined prolonged venous infusion plus pelvic XRT versus bolus 5FU plus leucovorin plus levamisole prior to and following combined pelvic XRT plus bolus 5FU plus leucovorin in patients with rectal cancer, phase III intergroup. NCCTG.

Stella P: Phase III intergroup randomized comparison of radiation alone versus pre-radiation chemotherapy for pure and mixed anaplastic oligodendrogliomas. NCCTG.

Stella P: A phase III study of radiotherapy of ABVD plus radiotherapy versus ABVD alone in the treatment of early stage hodgkin's disease.

Stella P: A randomized phase III trial of marimastat versus placebo in patients with metastatic breast cancer who have responding or stable disease after induction chemotherapy. EST.

Stella P: A phase III study of adriamycin/taxotere versus adriamycin/cytoxan for the adjuvant treatment of node positive or high risk node negative breast cancer. NCCTG.

Stella P: The influence of letrozole on bone mineral density in women with primary breast cancer completing five or more years of adjuvant tamoxifen. Consent to allow the evaluation of bone mineral density (optional). NCCTG.

Stella P: The influence of letrozole on bone mineral density in women with primary breast cancer completing five or more years of adjuvant tamoxifen. Consent to provide additional blood samples for lipid analysis. NCCTG.

Stella P: A randomized phase III trial of combinations of oxaliplatin (OXAL), 5-fluorouracil (5-FU) and irinotecan (CPT-11) as initial treatment of patients with advanced adenocarcinoma of the colon and rectum. NCCTG.

Stella P: A study of tamoxifen and raloxifene (STAR) for the prevention of breast cancer. NSABP.

Stella P: A phase II study of theophylline in chronic lymphocytic leukemia. EST.

Stella P: A prospectively randomized trial of low-dose leucovorin + 5FU, high dose leucovorin + 5FU, levamisole + 5FU or low dose leucovorin + 5FU + levamisole following curative resection in selected patients with dukes B or C colon cancer, phase III. SWOG.

RESEARCH PROJECTS (CONT.)

Stella P: A phase III randomized trial of 12 month versus 3 months of paclitaxel in patients with advanced ovarian cancer who attain a clinically defined complete response (CR) following platinum/paclitaxel based chemotherapy. SWOG.

Stella P: A phase II study of alternating cycles of fludarabine and clophosphamide in previously untreated patients with B-cell. NCCTG.

Stella P: Pilot trial of paclitaxel-herceptin adjuvant therapy for early stage breast cancer. EST.

Stella PJ, Arneson, W. Jr, Desrochers RP, Kimball BC, Kulick J: A randomized trial of axillary node dissection in women with clinical T1 or T2 NO MO breast cancer who have a positive sentinel node.

Stella P: A randomized, double-blind, multi-center, phase II study to assess the safety, tolerability, and efficacy in subjects with locally ZD6474 in combination with docetaxel (TAXOTERE) advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy.

Stella P: Phase II selection design trial of concurrent chemotherapy + cetuximab versus chemotherapy followed by cetuximab in advanced non-small cell lung cancer. NSCLC.

Stella P: A double-blind phase II study of BAY 43-9006 in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regimens. SWOG.

Stella P: A randomized phase II trial of paclitaxel, carboplatin and trastuzumab (herceptin) as first-line chemotherapy in patients with metastatic breast cancer which over expresses HER-2. NCCTG.

Stella P: Phase III trial of doxorubicin cyclophosphamide (AC) followed by weekly paclitaxel with or without trastuzumab as adjuvant treatment for women with HER-2 overexpressing node positive breast cancer. NCCTG.

Stella P: A Phase II Trial of Trastuzumab Plus Weekly Ixabepilone (BMS-247550) and Carboplatin in Patients with HER2/Neu-Positive Metastatic Breast Cancer. ECOG.

ARTICLES APPEARING IN SCIENTIFIC JOURNALS

Belani CP, Adak S, Aisner S, Stella PJ, Levitan N, Johnson DH; Eastern Cooperative Oncology Group. Docetaxel for malignant mesothelioma: Phase II study of the eastern cooperative oncology group. *Clin Lung Cancer*, 2004 Jul;8(1):43-7.

Delaunoit T, Golberg RM, Sargent DJ, Morton RF, Fuchs CS, Findlay BP, Thomas SP, Salim M, Schaefer PL, Stella PJ, Green F, Mailliard JA. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered combination with either irinotecan or oxaliplatin. *cancer*. 2004 Nov 15;101(10):2170-6.

Winegarden JD, Mauer AM, Otterson GA, Rudin CM, Villalona-Calero MA, Lanzotti VJ, Szeto L, Kasza K, Hoffman PC, Vokes EE; University of Chicago Phase II Network; Ohio State University. A phase II study of oxaliplatin and paclitaxel in patients with advanced non-small-cell lung cancer. *Ann Oncol*. 2004 Jun;15(6):915-20.

Croghan GA, Sloan JA, Croghan IT, Novotny P, Hurt RD, DeKrey WL, Mailliard JA, Ebbert LP, Swan DK, Walsh DJ, Wiesenfeld M, Levitt R, Stella P, Johnson PA, Tschetter LK, Loprinzi C. Comparison of nicotine patch alone versus nicotine nasal spray alone versus a combination for treating smokers: a minimal intervention, randomized multi-center trial in a nonspecialized setting. *Nicotine Tob Res*. 2003 Apr;5(2):181-7.

ARTICLES APPEARING IN SCIENTIFIC JOURNALS (CONT.)

Hurt RD, Krook JE, Croghan IT, Loprinzi CL, Sloan JA, Novotny PJ, Kardinal CG, Knost JA, Tirona MT, Addo F, Morton RF, Michalak JC, Schaefer PL, Porter PA, Stella PJ. Nicotine patch therapy based on smoking rate followed by bupropion for prevention of relapse to smoking. *J Clin Oncol.* 2003 Mar 1;21(5):914-20.

Jatoi A, Stella PJ, Hillman S, Mailliard JA, Vanone S, Perez EA, Cannon MW, Geyer S, Wiesenfeld M, Jett JR; Phase II north central cancer treatment group study. Weekly carboplatin and paclitaxel in elderly non-small-cell lung cancer patients (≥ 65 years of age). *Am J Clin Oncol.* 2003 Oct;26(5):441-7.

Jatoi A, Hillman S, Stella PJ, Mailliard JA, Sloan J, Vanone S, Cannon MW, Kutteh L, Kanard A, Jett JR. Daily activities: Exploring their spectrum and prognostic impact in order, chemotherapy-treated lung cancer patients. *Support Care Cancer.* 2003 Jul;11(7):460-4. Epub 2003 Mar 12.

Jatoi A, Suman VJ, Schaefer P, Block M, Loprinzi C, Roche P, Garneau S, Morton R, Stella PJ, Alberts SR, Pittelkow M, Sloan J, Pagano R. A phase II study of topical ceramides for cutaneous breast cancer. *Breast Cancer Res Treat.* 2003 Jul;80(1):99-104.

Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR. The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. *J Clin Oncol.* 2003 Sep 1;21(17).

Winegarden JD, Mauer AM, Gajewski TF, Hoffman PC, Krauss S, Rudin CM, Vokes EE. A phase II study of bryostatins and paclitaxel in patients with advanced non-small cell lung cancer. *Lung Cancer.* 2003 Feb;39(2):191-6.

ABSTRACTS, PRELIMINARY COMMUNICATIONS, PANEL DISCUSSIONS AND SCIENTIFIC MEETINGS

Jerome D, Winegarden JD, Villalona M, Mauer AM, Vokes E. A phase II trial of temozolomide and irinotecan as second-line treatment of advanced non-small cell lung cancer. Presented as a poster at the 10th World Conference of Lung Cancer, Vancouver, Canada, August 2003.